A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

NCT04592874 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: AL002
DRUG: Placebo

Sponsor

Alector Inc.